Abstract
In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Pusic, I. & DiPersio, J. F. The use of growth factors in hematopoietic stem cell transplantation. Curr. Pharm. Des. 14, 1950–1961 (2008).
Bensinger, W. et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol. 13, 2547–2555 (1995).
Lapidot, T. & Petit, I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol. 30, 973–981 (2002).
De Clercq, E. The bicyclam AMD3100 story. Nature Rev. Drug Discov. 2, 581–587 (2003).
Liles, W. C. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728–2730 (2003).
Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).
Broxmeyer, H. E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307–1318 (2005).
Burroughs, L. et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106, 4002–4008 (2005).
Devine, S. M. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1095–1102 (2004).
Flomenberg, N. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106, 1867–1874 (2005).
Pusic, I. et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol. Blood Marrow Transpl. 14, 1045–1056 (2008).
DiPersio, J. et al. A Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 445 (2007).
DiPersio, J. F. et al. A Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 601 (2007).
Micallef, I. et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the Phase III (3101-NHL) study. ASH Annual Meeting Abs. 110, 602 (2007).
Calandra, G. et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transpl. 41, 331–338 (2008).
IMS MIDAS (2007).
Reams, A. Wachovia Equity Research Report. (Wachovia Capital Markets, 9 Dec 2008).
Abrahams, B. Oppenheimer Equity Research Report. (Oppenheimer and Co., 3 Dec 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.F.D and G.L.U. have received honoraria and research support from Genzyme Corporation.
Rights and permissions
About this article
Cite this article
DiPersio, J., Uy, G., Yasothan, U. et al. Plerixafor. Nat Rev Drug Discov 8, 105–107 (2009). https://doi.org/10.1038/nrd2819
Issue date:
DOI: https://doi.org/10.1038/nrd2819
This article is cited by
-
Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling
Journal of Mathematical Biology (2023)
-
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
Bone Marrow Transplantation (2020)
-
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Bone Marrow Transplantation (2020)
-
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
Bone Marrow Transplantation (2020)
-
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Nature Communications (2020)
